OncoMatch/Clinical Trials/NCT06374602
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Is NCT06374602 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pembrolizumab + Lenvatinib for anaplastic thyroid cancer.
Treatment: Pembrolizumab + Lenvatinib — This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Biomarker criteria
Allowed: BRAF V600 mutation
patients with a mutation in the BRAF V600 gene without previous targeted therapy with BRAF/MEK inhibitors
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational drugs
Lab requirements
Blood counts
adequate function of internal organs and bone marrow
Kidney function
adequate function of internal organs and bone marrow
Liver function
adequate function of internal organs and bone marrow
adequate function of internal organs and bone marrow
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06374602 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drugs disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify